NYSEHealth CareHealth Care EquipmentS&P MidCap 400
$319.21
-1.90 (-0.59%)
Close of Nov 06, 2026 · end-of-day data
PEN 8-K filings, explained
Every material Form 8-K Penumbra has filed with the SEC since November 02, 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Penumbra reported third quarter 2026 revenue of $410.1 million, representing a 15.6% increase compared to the third quarter of 2025. Net income for the quarter was $42.3 million, down from $45.9 million in the prior year period. Due to the pending acquisition by Boston Scientific Corporation, the company did not provide full-year 2026 financial guidance.
Revenue reached $410.1 million in the third quarter of 2026, up 15.6% year-over-year.
Global thrombectomy revenue grew 18.1% to $279.2 million for the quarter ended September 30, 2026.
Net income for the third quarter of 2026 was $42.3 million, yielding diluted net income per share of $1.07.
Operating expenses totaled $229.6 million, including $7.1 million in acquisition-related expenses tied to the pending Boston Scientific transaction.
Penumbra reported second-quarter 2026 revenue of $390.0 million, up 14.9% from a year earlier, but net income fell to $34.8 million from $45.3 million and diluted earnings per share dropped to $0.88 from $1.15. The company will not provide full-year 2026 guidance or hold a earnings call because of its pending acquisition by Boston Scientific Corporation, leaving shareholders without a current outlook.
Q2 2026 revenue was $390.0 million, up 14.9%; thrombectomy rose 12.5% to $259.0 million and embolization and access rose 20.0% to $131.1 million.
Q2 2026 net income was $34.8 million versus $45.3 million a year earlier; the provision for income taxes was $11.4 million compared with $40 thousand.
SG&A included $6.9 million of acquisition-related expenses tied to the pending acquisition by Boston Scientific Corporation, and no full-year 2026 financial guidance will be provided.
Penumbra reported first quarter 2026 revenue of $374.8 million, up 15.6% from a year earlier, but net income fell to $32.6 million from $39.2 million and diluted earnings per share fell to $0.82 from $1.00. The company will not provide full-year 2026 guidance or hold an earnings call because of its pending acquisition by Boston Scientific.
Revenue of $374.8 million, up 15.6%; thrombectomy up 12.1% to $253.9 million and embolization and access up 23.8% to $120.8 million
Net income of $32.6 million versus $39.2 million in Q1 2025; diluted EPS of $0.82 versus $1.00
$9.4 million of acquisition-related expenses included in SG&A, tied to the pending Boston Scientific acquisition
No full-year 2026 financial guidance and no conference call, due to the pending Boston Scientific acquisition
Penumbra reported fourth quarter 2025 revenue of $385.4 million, up 22.1%, and net income of $47.3 million, compared with $33.7 million a year earlier. Full-year 2025 revenue rose 17.5% to $1,403.7 million and net income reached $177.7 million, versus $14.0 million in 2024. The company will not provide 2026 financial guidance or hold a conference call because of its proposed acquisition by Boston Scientific.
Q4 2025 diluted EPS was $1.20, compared with $0.86 in Q4 2024.
Full-year 2025 income from operations was $189.2 million, compared with $9.3 million in 2024.
No financial guidance for full-year 2026 because of the proposed acquisition by Boston Scientific Corporation (NYSE: BSX).
Penumbra agreed on January 14, 2026 to merge with Boston Scientific, which will acquire it in a deal valued at $374 per share and an enterprise value of approximately $14.5 billion. The same day, Penumbra released preliminary fourth quarter and full year 2025 revenue that grew 17.3% to 17.5% for the year, and the merger requires Penumbra stockholder approval and other closing conditions.
Each Penumbra share can be exchanged for $374 in cash or 3.8721 Boston Scientific shares, subject to proration to about 73% cash and 27% stock.
Boston Scientific expects to finance the approximately $11 billion cash portion with cash on hand and new debt.
The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary conditions, and Penumbra stock would be delisted from the NYSE.
Preliminary full year 2025 revenue of $1,401.3 million to $1,403.1 million, up 17.3% to 17.5%; fourth quarter revenue of $383.0 million to $384.8 million, up 21.4% to 22.0%.
Penumbra appointed Shruthi Narayan as President effective September 1, 2025, while Adam Elsesser continues as Chairman and CEO. The filing also discloses a related-person IT services arrangement with a company led by Ms. Narayan's spouse, and an equity grant of about $2.5 million to Ms. Narayan.
Shruthi Narayan appointed President effective September 1, 2025; board action dated August 22, 2025
Equity grant of restricted stock units valued at approximately $2.5 million, vesting in equal annual installments over four years
Payments to N28 Technologies, led by Ms. Narayan's spouse, total approximately $2 million since January 1, 2024
Penumbra reported first quarter 2025 revenue of $324.1 million, up 16.3% from a year earlier, and net income of $39.2 million, compared with $11.0 million in the first quarter of 2024. The company reiterated its full-year 2025 revenue guidance of $1,340 million to $1,360 million and raised its U.S. Thrombectomy growth outlook to 20% to 21%.
Revenue $324.1 million, up 16.3% (16.9% in constant currency) from $278.7 million in Q1 2024
Net income $39.2 million, or $1.00 diluted EPS, versus $11.0 million, or $0.28 diluted EPS, a year earlier
Full-year 2025 revenue guidance of $1,340 million to $1,360 million reiterated
U.S. Thrombectomy growth guidance raised to 20% to 21% from 19% to 20%
Penumbra said director Don Kassing notified the company on February 14, 2025 that he will retire from its board effective April 1, 2025. The filing states his decision did not involve any disagreement with the company, and it contains no financial results or guidance.
Don Kassing, a board member since 2008 and Presiding Director since 2015, will retire effective April 1, 2025.
Notice to the company was dated February 14, 2025; the press release was issued February 21, 2025.
Board chair, president and CEO Adam Elsesser thanked Kassing for his service over 17 years.
The filing states Kassing's decision did not involve any disagreement with the company.
Penumbra reported fourth-quarter and full-year 2024 results, with revenue up 10.8% in the quarter and 12.9% for the year. Net income fell sharply, to $14.0 million for the year from $91.0 million in 2023, largely due to a $76.9 million impairment charge tied to its Immersive Healthcare business. The company projected 2025 revenue of $1,340.0 million to $1,360.0 million, growth of 12% to 14%.
Q4 2024 revenue was $315.5 million, up 10.8% from $284.7 million; Q4 net income was $33.7 million versus $54.2 million a year earlier.
Full-year 2024 revenue was $1,194.6 million, up 12.9%, but income from operations fell to $9.3 million from $73.6 million.
The 2024 results include a $76.9 million impairment charge and a $5.8 million Italian government payback provision.
For 2025, the company projects total revenue of $1,340.0 million to $1,360.0 million and operating margin of 13% to 14%.
Penumbra reported third-quarter 2024 revenue of $301.0 million, up 11.1% from a year earlier, and GAAP net income of $29.5 million, versus $9.2 million in the same quarter of 2023. It reiterated full-year 2024 revenue guidance of $1,180.0 million to $1,200.0 million and raised the low end of its U.S. thrombectomy growth outlook to 24% to 25%, from 23% to 25%.
Q3 2024 GAAP diluted EPS was $0.75, versus $0.23 a year earlier; non-GAAP diluted EPS was $0.85, versus $0.67.
Q3 2024 included $5.0 million in one-time expenses tied to the wind down of the Immersive Healthcare business.
Nine-month 2024 GAAP net loss was $19.7 million, including a $76.9 million impairment charge, and the company kept its 2024 revenue guidance unchanged.
Penumbra reported second-quarter 2024 revenue of $299.4 million, up 14.5% from a year earlier, but posted a GAAP net loss of $60.2 million after a $110.3 million impairment charge tied to its immersive healthcare assets. The company also lowered its full-year 2024 revenue guidance to $1,180 million to $1,200 million, down $60 million at the midpoint from $1,230 million to $1,270 million, which weighs on the outlook for shareholders.
Q2 2024 revenue of $299.4 million, up 14.5%; U.S. thrombectomy revenue rose 24.9% to $153.7 million
2024 revenue guidance cut to $1,180 million to $1,200 million from $1,230 million to $1,270 million, with the China and European businesses cited as main drivers
Non-GAAP income from operations of $31.7 million and adjusted EBITDA of $46.3 million for the quarter
Penumbra reported first-quarter 2024 revenue of $278.7 million, up 15.4% from a year earlier, and GAAP net income of $11.0 million, or $0.28 per diluted share, compared with $8.6 million, or $0.22, in the first quarter of 2023. The company reiterated its full-year 2024 revenue guidance of $1,230.0 million to $1,270.0 million, which reflects 16% to 20% growth.
Revenue of $278.7 million, up 15.4% from $241.4 million; U.S. revenue rose 22.0% while international revenue fell 0.7%.
GAAP net income of $11.0 million, or $0.28 per diluted share, versus $8.6 million, or $0.22, a year earlier.
Operating expenses included $4.8 million in non-recurring litigation-related expenses in the first quarter of 2024.
Full-year 2024 total revenue guidance of $1,230.0 million to $1,270.0 million was reiterated, and U.S. thrombectomy growth guidance of 27% to 30% was also kept.
Penumbra reported fourth-quarter 2023 revenue of $284.7 million, up 28.7%, and GAAP net income of $54.2 million, or $1.38 per diluted share, which includes a $25.5 million tax benefit from a valuation allowance release. For 2024, the company projects total revenue of $1,230.0 million to $1,270.0 million, or 16% to 20% growth, and expects U.S. thrombectomy revenue to grow 27% to 30%.
Q4 2023 revenue was $284.7 million, up 28.7%; thrombectomy revenue was $190.8 million, up 42.4%
Q4 2023 GAAP net income was $54.2 million, or $1.38 per diluted share, including a $25.5 million tax benefit
Full-year 2023 revenue was $1,058.5 million, up 25.0%, and GAAP income from operations was $73.6 million versus $6.1 million in 2022
2024 revenue is projected at $1,230.0 million to $1,270.0 million, or 16% to 20% growth over 2023
Penumbra reported third-quarter 2023 results, with revenue up 26.8% from a year earlier and GAAP net income of $9.2 million, compared with a net loss of $2.3 million in the third quarter of 2022. The company also said it expects fourth-quarter revenue growth of 28% to 31% and cited full-year 2023 revenue guidance of $1.05 billion to $1.07 billion.
Q3 2023 revenue was $270.9 million, up 26.8% (25.9% in constant currency) from $213.7 million in Q3 2022.
GAAP income from operations was $12.6 million, including a one-time $18.2 million acquired in-process R&D expense; non-GAAP income from operations was $33.2 million.
Thrombectomy product revenue rose 38.0% to $179.1 million, a company record.
Full-year 2023 revenue guidance is $1.05 billion to $1.07 billion, with fourth-quarter growth expected at 28% to 31%.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Penumbra filing is on SEC EDGAR ↗. 8-K briefs of other companies →